28 results on '"Hegenbart, Ute"'
Search Results
2. Versorgung von Patienten mit kardialer Amyloidose: Konsensuspapier der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung e. V. (DGK), AG 40 Onkologische Kardiologie, und der Deutschen Gesellschaft für Hämatologie und medizinische Onkologie e. V. (DGHO), der Deutschen Gesellschaft für Neurologie e. V. (DGN) und der Deutschen Gesellschaft für Nephrologie e. V. (DGfN)
3. Healthcare Resource Utilization and Cost-of-Illness in Systemic Light Chain (AL) Amyloidosis in Europe: Results From the Real-World, Retrospective EMN23 Study
4. Prognostic impact of cytogenetic abnormalities detected by FISH in AL amyloidosis with daratumumab-based frontline therapy
5. Identification of isoaspartate-modified transthyretin as potential target for selective immunotherapy of transthyretin amyloidosis
6. Patient experiences of interprofessional collaboration and intersectoral communication in rare disease healthcare in Germany – a mixed-methods study
7. Prognostic impact of cytogenetic abnormalities by FISH in systemic AL amyloidosis in the era of daratumumab and bortezomib-based frontline combination regimens
8. Proposed hematologic progression criterion in patients with AL amyloidosis.
9. RV-PA uncoupling is a strong predictor of mortality in transthyretin amyloid cardiomyopathy.
10. Fat aspiration for minimally-invasive amyloidosis screening from an external amyloidosis clinic
11. Stem cell collection in AL patients after different induction and mobilization therapies
12. A Platform for Federated Acquisition of Health-related Quality of Life Data in Systemic Amyloidosis
13. Long-term evaluation of amyloidosis diseases in Germany: National Clinical Amyloidosis Registry
14. Biomarker-based renal response and progression criteria in AA amyloidosis: results from the testing cohort of the Pavia-Heidelberg study
15. Patient-reported Diagnostic Journey of Patients Recently Diagnosed with Transthyretin Amyloidosis: Data from the Amyloidosis Research Consortium’s 2022 and 2023 Amyloidosis Community Surveys
16. bDMARD can prevent the progression of AA amyloidosis to end-stage renal disease
17. Prognostic Value of Standard Heart Failure Medication in Patients with Cardiac Transthyretin Amyloidosis
18. T2-relaxometry in a large cohort of hereditary transthyretin amyloidosis with polyneuropathy.
19. Response to therapy with tafamidis 61 mg in patients with cardiac transthyretin amyloidosis: real-world experience since approval.
20. HOVON 104, long‐term follow‐up of bortezomib‐dexamethasone induction therapy followed by autologous stem cell transplantation in newly diagnosed AL amyloidosis patients.
21. Teclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case series
22. Light chain mutations contribute to defining the fibril morphology in systemic AL amyloidosis.
23. Sequence diversity of kappa light chains from patients with AL amyloidosis and multiple myeloma.
24. Anterior Aortic Plane Systolic Excursion: A Novel Indicator of Transplant-Free Survival in Systemic Light-Chain Amyloidosis
25. Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain Amyloidosis.
26. Development and Validation of Staging Systems for AA Amyloidosis.
27. Autologous-allogeneic versus autologous tandem stem cell transplantation and maintenance therapy with thalidomide for multiple myeloma patients under 60 years of age: a prospective, phase II study.
28. Daratumumab in first-line treatment of patients with light chain amyloidosis and Mayo stage IIIb improves treatment response and overall survival.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.